Skip to main content

Table 2 Regression analysis for MV duration and LOS

From: Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Outcomes Crude analysis p-value Beta coefficient (estimates) (95% CI) p-value$*
Control group Tocilizumab group
MV duration during ICU stay days, median (Q1, Q3)&# 9.0 (4.0, 17.0) 10.0 (4.0, 18.0) 0.46 0.06 (− 0.11, 0.22) 0.49
ICU length of stay days, median (Q1, Q3)& 8.0 (5.0, 13.0) 9.0 (6.0, 15.0) 0.01 0.12 (− 0.05, 0.29) 0.16
Hospital length of stay days, median (Q1, Q3)& 16.0 (11.0, 26.0) 18.0 (13.0, 27.5) 0.04 0.15 (− 0.00, 0.29) 0.05
  1. $*Multivariable negative binomial regression is used after adjusting for patient’s age, SOFA score, PaO2/FiO2 ratio baseline and systemic corticosteroids during ICU stay to calculate estimates and p-value
  2. &#Denominator is patients who have respiratory failure requiring MV during ICU stay
  3. &Denominator is patients who survived